Network Bio has raised $50 million, according to a Techmeme summary of a Wall Street Journal report by Brian Gormley. The company is described as developing an AI foundation model built from datasets of patient tissue and blood samples. The available summary says those datasets are being created by pooling access to biobanks. That makes the reported funding round less about a standalone model release and more about assembling the biological data access needed to train one. Key deal details are not available in the provided item. The summary does not identify the investors, valuation, round type, timing, customers, or technical specifications for the model. It also includes only a truncated reference to Network Bio’s plans, so those plans should not be treated as confirmed here. Who benefits: Network Bio benefits from fresh capital and from the reported strategy of pooling biobank access. Biobanks participating in such data arrangements may also gain a route into AI-model development, though the provided item does not specify terms. Who's exposed: Competing biomedical AI companies without comparable access to patient-derived datasets could be disadvantaged if Network Bio’s approach proves useful. That remains an inference from the reported data strategy, not a confirmed market outcome.